Thursday, 15 October 2026European Markets

PERNOD RICARD, REMY COINTREAU, Another 1 Companies Have A High Dividend Yield And Return On Equity In The Beverages - Wineries & Distilleries Industry.

Loading stream...

(vianews) - pernod ricard (ri.pa) is among this list of stock assets with the highest dividend rate and return on equity on the beverages - wineries & distilleries industry.

financial asset price forward dividend yield return on equity
pernod ricard (ri.pa) €149.95 3.78% 12.18%
remy cointreau (rco.pa) €93.44 2.5% 10.24%
lucasbols (bols.as) €16.05 2.06% 3.22%

several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. pernod ricard (ri.pa)

3.78% forward dividend yield and 12.18% return on equity

pernod ricard sa produces and sells wines and spirits worldwide. the company offers whiskey, vodka, gin, rum, liqueur and bitters, champagne, tequila and mezcal, and aperitif under the brands 100 pipers, aberlour, absolut, absolut elyx, altos, ararat, augier, avion, ballantine's, becherovka, beefeater, blenders pride, brancott estate, campo viejo, ceder's, chivas, church road, clan campbell, del maguey, george wyndham, green spot, havana club, imperial, imperial blue, italicus, j.p. wiser's, jacob's creek, jameson, jefferson's, kahlúa, kenwood, ki no bi, lillet, long john, l'orbe, lot no. 40, malfy, malibu, martell, method & madness, midleton very rare, minttu, monkey 47, mumm, olmeca, ostoya, passport scotch, pastis 51, pernod, perrier-jouët, plymouth gin, powers, rabbit hole, ramazzotti, redbreast, ricard, royal salute, royal stag, scapa, seagram's gin, secret speyside, smooth ambler, something special, st hugo, stoneleigh, suze, the glenlivet, tx, wyborowa, and ysios. it also provides non-alcoholic beverages under the brands ceder's, suze tonic 0%, cinzano spritz 0%, pacific, campo viejo sparkling 0%, and jacob's creek unvined. pernod ricard sa was founded in 1805 and is headquartered in paris, france.

earnings per share

as for profitability, pernod ricard has a trailing twelve months eps of €8.04.

pe ratio

pernod ricard has a trailing twelve months price to earnings ratio of 18.65. meaning, the purchaser of the share is investing €18.65 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 12.18%.

moving average

pernod ricard's value is above its 50-day moving average of €142.06 and below its 200-day moving average of €154.27.

sales growth

pernod ricard's sales growth is 7.9% for the ongoing quarter and 7.9% for the next.

more news about pernod ricard.

2. remy cointreau (rco.pa)

2.5% forward dividend yield and 10.24% return on equity

rémy cointreau sa, together with its subsidiaries, engages in the production, sale, and distribution of liqueurs and spirits. the company operates through rémy martin, liqueurs & spirits, and partner brands segments. it offers liqueurs, brandy, gin, single malt whisky, rum, wine, and champagne primarily under the cointreau, metaxa, st-rémy, mount gay, bruichladdich, port charlotte, octomore, the botanist, westland, louis xiii, and domaine des hautes glaces brands. the company operates in europe, the middle east, africa, the americas, asia, australia, and new zealand. rémy cointreau sa was founded in 1724 and is headquartered in cognac, france.

earnings per share

as for profitability, remy cointreau has a trailing twelve months eps of €3.6.

pe ratio

remy cointreau has a trailing twelve months price to earnings ratio of 25.96. meaning, the purchaser of the share is investing €25.96 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 10.24%.

volume

today's last reported volume for remy cointreau is 109846 which is 8.2% below its average volume of 119658.

yearly top and bottom value

remy cointreau's stock is valued at €93.44 at 12:40 est, way below its 52-week high of €158.15 and way higher than its 52-week low of €79.30.

more news about remy cointreau.

3. lucasbols (bols.as)

2.06% forward dividend yield and 3.22% return on equity

lucas bols n.v. engages in the development, bottling, marketing, distribution, and sale of cocktail and spirits worldwide. it offers a range of spirits products, including liqueurs, genever, gin, and vodka under the bols, galliano, passoã, bokma, bols genevers, coebergh, damrak, hartevelt, henkes, hoppe, floryn, legner, klm houses, nuvo, pallini, pisang ambon, tequila partida, vaccari, wynand fockink, fluère, and zwarte kip brands. the company was founded in 1575 and is headquartered in amsterdam, the netherlands.

earnings per share

as for profitability, lucasbols has a trailing twelve months eps of €0.47.

pe ratio

lucasbols has a trailing twelve months price to earnings ratio of 34.15. meaning, the purchaser of the share is investing €34.15 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 3.22%.

sales growth

lucasbols's sales growth for the current quarter is 11.3%.

more news about lucasbols.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com